FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063484906> ?p ?o ?g. }

• W2063484906 endingPage "661.e6" @default.
• W2063484906 startingPage "654" @default.
• W2063484906 abstract "Elevated heart rate in stable coronary artery disease (CAD) is associated with worse outcomes, particularly increased risk of myocardial infarction. Heart rate reduction with the If inhibitor ivabradine confers symptomatic benefits in angina pectoris and reduces coronary events in patients with stable CAD and left ventricular (LV) systolic dysfunction, with a resting heart rate of ≥70 beats/min. The SIGNIFY trial is testing the hypothesis that heart rate reduction using ivabradine reduces mortality and cardiovascular events in patients with stable CAD, but without clinical heart failure.The SIGNIFY trial is a randomized, double-blind, parallel-group, placebo-controlled, event-driven study in patients with stable CAD (1,139 centers, 51 countries). Participants are 55 years or older, with stable CAD and an LV ejection fraction >40%, in sinus rhythm, with a baseline resting heart rate of ≥70 beats/min, and with at least 1 additional cardiovascular risk factor. At inclusion, patients receive ivabradine 7.5 mg twice a day or matching placebo, which is adjusted at every visit to a heart rate target of 60 beats/min. Participants should receive the best possible background treatment for stable CAD. The primary end point is a composite of cardiovascular death or nonfatal myocardial infarction.Recruitment lasted from October 2009 to April 2012. The SIGNIFY trial has recruited 19,102 patients (age 65.0 ± 7.2 years, resting heart rate 77.2 ± 7.0 beats/min, 72% male) with no evidence for LV dysfunction (ejection fraction 56.5% ± 8.6%).The SIGNIFY trial will shed further light on the role of heart rate lowering with ivabradine in patients with stable CAD without clinical heart failure. The study is expected to end in 2014." @default.
• W2063484906 created "2016-06-24" @default.
• W2063484906 creator A5003831287 @default.
• W2063484906 creator A5007737202 @default.
• W2063484906 creator A5016095791 @default.
• W2063484906 creator A5049309607 @default.
• W2063484906 creator A5062655570 @default.
• W2063484906 creator A5073792258 @default.
• W2063484906 date "2013-10-01" @default.
• W2063484906 modified "2023-10-04" @default.
• W2063484906 title "Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure" @default.
• W2063484906 cites W1970516435 @default.
• W2063484906 cites W1979947635 @default.
• W2063484906 cites W2010396034 @default.
• W2063484906 cites W2046746746 @default.
• W2063484906 cites W2078034341 @default.
• W2063484906 cites W2078656599 @default.
• W2063484906 cites W2097992015 @default.
• W2063484906 cites W2099693424 @default.
• W2063484906 cites W2102948895 @default.
• W2063484906 cites W2112021997 @default.
• W2063484906 cites W2112664451 @default.
• W2063484906 cites W2119493017 @default.
• W2063484906 cites W2129134633 @default.
• W2063484906 cites W2135491318 @default.
• W2063484906 cites W2136642260 @default.
• W2063484906 cites W2142164422 @default.
• W2063484906 cites W2142264046 @default.
• W2063484906 cites W2144207672 @default.
• W2063484906 cites W2145270758 @default.
• W2063484906 cites W2145318712 @default.
• W2063484906 cites W2146561080 @default.
• W2063484906 cites W2154143064 @default.
• W2063484906 cites W2156920951 @default.
• W2063484906 cites W2163823318 @default.
• W2063484906 cites W2164145340 @default.
• W2063484906 cites W2168283808 @default.
• W2063484906 cites W2170059806 @default.
• W2063484906 cites W4292172722 @default.
• W2063484906 doi "https://doi.org/10.1016/j.ahj.2013.06.024" @default.
• W2063484906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24093844" @default.
• W2063484906 hasPublicationYear "2013" @default.
• W2063484906 type Work @default.
• W2063484906 sameAs 2063484906 @default.
• W2063484906 citedByCount "28" @default.
• W2063484906 countsByYear W20634849062014 @default.
• W2063484906 countsByYear W20634849062015 @default.
• W2063484906 countsByYear W20634849062016 @default.
• W2063484906 countsByYear W20634849062017 @default.
• W2063484906 countsByYear W20634849062019 @default.
• W2063484906 countsByYear W20634849062020 @default.
• W2063484906 countsByYear W20634849062021 @default.
• W2063484906 crossrefType "journal-article" @default.
• W2063484906 hasAuthorship W2063484906A5003831287 @default.
• W2063484906 hasAuthorship W2063484906A5007737202 @default.
• W2063484906 hasAuthorship W2063484906A5016095791 @default.
• W2063484906 hasAuthorship W2063484906A5049309607 @default.
• W2063484906 hasAuthorship W2063484906A5062655570 @default.
• W2063484906 hasAuthorship W2063484906A5073792258 @default.
• W2063484906 hasBestOaLocation W20634849062 @default.
• W2063484906 hasConcept C126322002 @default.
• W2063484906 hasConcept C142724271 @default.
• W2063484906 hasConcept C164705383 @default.
• W2063484906 hasConcept C168563851 @default.
• W2063484906 hasConcept C203092338 @default.
• W2063484906 hasConcept C204787440 @default.
• W2063484906 hasConcept C27081682 @default.
• W2063484906 hasConcept C2775914520 @default.
• W2063484906 hasConcept C2777953023 @default.
• W2063484906 hasConcept C2778198053 @default.
• W2063484906 hasConcept C2778213512 @default.
• W2063484906 hasConcept C2778425758 @default.
• W2063484906 hasConcept C2779161974 @default.
• W2063484906 hasConcept C2779167562 @default.
• W2063484906 hasConcept C500558357 @default.
• W2063484906 hasConcept C71924100 @default.
• W2063484906 hasConcept C78085059 @default.
• W2063484906 hasConcept C84393581 @default.
• W2063484906 hasConceptScore W2063484906C126322002 @default.
• W2063484906 hasConceptScore W2063484906C142724271 @default.
• W2063484906 hasConceptScore W2063484906C164705383 @default.
• W2063484906 hasConceptScore W2063484906C168563851 @default.
• W2063484906 hasConceptScore W2063484906C203092338 @default.
• W2063484906 hasConceptScore W2063484906C204787440 @default.
• W2063484906 hasConceptScore W2063484906C27081682 @default.
• W2063484906 hasConceptScore W2063484906C2775914520 @default.
• W2063484906 hasConceptScore W2063484906C2777953023 @default.
• W2063484906 hasConceptScore W2063484906C2778198053 @default.
• W2063484906 hasConceptScore W2063484906C2778213512 @default.
• W2063484906 hasConceptScore W2063484906C2778425758 @default.
• W2063484906 hasConceptScore W2063484906C2779161974 @default.
• W2063484906 hasConceptScore W2063484906C2779167562 @default.
• W2063484906 hasConceptScore W2063484906C500558357 @default.
• W2063484906 hasConceptScore W2063484906C71924100 @default.
• W2063484906 hasConceptScore W2063484906C78085059 @default.
• W2063484906 hasConceptScore W2063484906C84393581 @default.
• W2063484906 hasIssue "4" @default.
• W2063484906 hasLocation W20634849061 @default.

• next